- Giacomini, Kathleen;
- Witte, John;
- Andreadis, Charalambos;
- Yee, SW;
- Mefford, JA;
- Singh, N;
- Percival, ME;
- Stecula, A;
- Yang, K;
- Witte, JS;
- Takahashi, A;
- Kubo, M;
- Matsuda, K
Acute myeloid leukemia (AML) is a clinically heterogeneous disease, with a 5-year disease-free survival (DFS) ranging from under 10% to over 70% for distinct groups of patients. At our institution, cytarabine, etoposide and busulfan are used in first or se
